However, treatment with the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib provided only a seven-year 21.2% PFS and 27.4% OS in 192 patients with unresectable or metastatic BRAF-mutant melanoma who were treatment-naïve or had progressed on first-line immunotherapy (7). This evidence concerns the gene MAP2K7 and melanoma.